AstraZeneca Pharma India 過去の業績
過去 基準チェック /16
AstraZeneca Pharma Indiaは、平均年間13.1%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間13.3% 12.3%収益成長率で 成長しています。 AstraZeneca Pharma Indiaの自己資本利益率は12.1%であり、純利益率は5.5%です。
主要情報
13.1%
収益成長率
13.1%
EPS成長率
Pharmaceuticals 業界の成長 | 17.5% |
収益成長率 | 12.3% |
株主資本利益率 | 12.1% |
ネット・マージン | 5.5% |
前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors
Sep 18We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability
Jun 03Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S
May 22We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?
Aug 02収支内訳
収支内訳
AstraZeneca Pharma India の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Sep 24 | 14,845 | 819 | 2,602 | 0 |
30 Jun 24 | 13,876 | 959 | 2,496 | 0 |
31 Mar 24 | 12,955 | 1,615 | 2,474 | 0 |
31 Dec 23 | 11,970 | 1,393 | 2,709 | 0 |
30 Sep 23 | 11,410 | 1,528 | 2,633 | 0 |
30 Jun 23 | 10,661 | 1,330 | 2,567 | 0 |
31 Mar 23 | 10,030 | 993 | 2,608 | 0 |
31 Dec 22 | 9,502 | 1,100 | 2,647 | 0 |
30 Sep 22 | 9,009 | 921 | 2,552 | 0 |
30 Jun 22 | 8,625 | 715 | 2,483 | 0 |
31 Mar 22 | 8,056 | 616 | 2,345 | 0 |
31 Dec 21 | 7,839 | 609 | 2,279 | 0 |
30 Sep 21 | 7,836 | 705 | 2,231 | 0 |
30 Jun 21 | 7,954 | 849 | 2,236 | 0 |
31 Mar 21 | 8,136 | 933 | 2,227 | 0 |
31 Dec 20 | 7,982 | 756 | 2,245 | 0 |
30 Sep 20 | 8,218 | 813 | 2,196 | 0 |
30 Jun 20 | 8,208 | 693 | 2,176 | 0 |
31 Mar 20 | 8,318 | 722 | 2,196 | 0 |
31 Dec 19 | 8,272 | 725 | 2,070 | 0 |
30 Sep 19 | 8,185 | 749 | 2,104 | 0 |
30 Jun 19 | 7,714 | 696 | 1,998 | 0 |
31 Mar 19 | 7,283 | 545 | 2,061 | 0 |
31 Dec 18 | 6,887 | 478 | 1,956 | 0 |
30 Sep 18 | 6,021 | 83 | 1,887 | 0 |
30 Jun 18 | 6,050 | 265 | 1,837 | 0 |
31 Mar 18 | 5,710 | 259 | 1,557 | 0 |
31 Dec 17 | 5,319 | 175 | 1,493 | 0 |
30 Sep 17 | 5,536 | 442 | 1,439 | 0 |
30 Jun 17 | 5,275 | 176 | 2,105 | 0 |
31 Mar 17 | 5,437 | 201 | 1,587 | 0 |
31 Dec 16 | 5,866 | 279 | 1,818 | 0 |
30 Sep 16 | 5,809 | 206 | 1,777 | 0 |
30 Jun 16 | 5,711 | 131 | 1,732 | 0 |
31 Mar 16 | 5,637 | 53 | 1,768 | 0 |
31 Dec 15 | 5,529 | 428 | 2,892 | 0 |
30 Sep 15 | 5,166 | 207 | 2,934 | 0 |
30 Jun 15 | 4,753 | -5 | 1,546 | 0 |
31 Mar 15 | 4,690 | -208 | 1,715 | 0 |
31 Dec 14 | 4,624 | -615 | 2,948 | 103 |
30 Sep 14 | 4,732 | -466 | 2,906 | 103 |
30 Jun 14 | 4,742 | -199 | 1,702 | 0 |
31 Mar 14 | 4,737 | -5 | 2,773 | 103 |
31 Dec 13 | 4,545 | -165 | 2,555 | 164 |
質の高い収益: ASTRAZEN 非現金収入 のレベルが高いです。
利益率の向上: ASTRAZENの現在の純利益率 (5.5%)は、昨年(13.4%)よりも低くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: ASTRAZENの収益は過去 5 年間で年間13.1%増加しました。
成長の加速: ASTRAZENは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。
収益対業界: ASTRAZENは過去 1 年間で収益成長率がマイナス ( -46.4% ) となったため、 Pharmaceuticals業界平均 ( 20.5% ) と比較することが困難です。
株主資本利益率
高いROE: ASTRAZENの 自己資本利益率 ( 12.1% ) は 低い とみなされます。